Gantenerumab’s Phase 3 Flop Means Lecanemab Emerges As Favorite In Antibody Class Targeting Amyloid Plaque In Alzheimer’s Patients

Gantenerumab’s flop in Phase 3 means that lecanemab emerges as the preliminary favorite in the antibody class of biologics targeting beta-amyloid plaque in Alzheimer’s Disease patients. But, several key market access challenges lie ahead for the Alzheimer’s drug, should it get FDA approval in 2023.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive